{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:56:05Z","timestamp":1761486965054,"version":"3.41.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1023\/a:1023066304473","type":"journal-article","created":{"date-parts":[[2003,4,7]],"date-time":"2003-04-07T22:17:24Z","timestamp":1049753844000},"page":"195-201","source":"Crossref","is-referenced-by-count":28,"title":["Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States)"],"prefix":"10.1007","volume":"14","author":[{"given":"Polly A.","family":"Newcomb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Trentham-Dietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5115259_CR1","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/jnci\/89.15.1110","volume":"89","author":"MC Pike","year":"1997","unstructured":"Pike MC,Peters RK,Cozen W, et al. (1997) Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst\n89: 1110-1116.","journal-title":"J Natl Cancer Inst"},{"key":"5115259_CR2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.298.6667.147","volume":"298","author":"I Persson","year":"1989","unstructured":"Persson I,Adami HO,Bergkvist L, et al. (1989) Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Brit Med J\n298: 147-151.","journal-title":"Brit Med J"},{"key":"5115259_CR3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/0140-6736(91)90417-N","volume":"338","author":"LF Voigt","year":"1991","unstructured":"Voigt LF,Weiss NS,Chu J,Daling JR,McKnight B,van Belle G (1991) Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet\n338: 274-277.","journal-title":"Lancet"},{"key":"5115259_CR4","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/jnci\/91.13.1131","volume":"91","author":"E Weiderpass","year":"1999","unstructured":"Weiderpass E,Adami HO,Baron JA, et al. (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst\n91: 1131-1137.","journal-title":"J Natl Cancer Inst"},{"key":"5115259_CR5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00001648-199301000-00005","volume":"4","author":"SS Jick","year":"1993","unstructured":"Jick SS,Walker AM,Jick H (1993) Estrogens, progesterone, and endometrial cancer. Epidemiol\n4: 20-24.","journal-title":"Epidemiol"},{"key":"5115259_CR6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/0029-7844(94)00383-O","volume":"85","author":"D Grady","year":"1995","unstructured":"Grady D,Gebretsadik T,Kerlikowske K,Ernster V,Petitti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obst Gynecol\n85: 304-313.","journal-title":"Obst Gynecol"},{"key":"5115259_CR7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.1996.03530290040035","volume":"275","author":"The Writing Group for the PEPI Trial","year":"1996","unstructured":"The Writing Group for the PEPI Trial (1996) Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen\/Progestin Interventions (PEPI) Trial. JAMA\n275: 370-375.","journal-title":"JAMA"},{"key":"5115259_CR8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0002-9378(13)90437-3","volume":"170","author":"JD Woodruff","year":"1994","unstructured":"Woodruff JD,Pickar JH (1994) Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol\n170: 1213-1223.","journal-title":"Am J Obstet Gynecol"},{"key":"5115259_CR9","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(96)07365-5","volume":"349","author":"SA Beresford","year":"1997","unstructured":"Beresford SA,Weiss NS,Voigt LF,McKnight B (1997) Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet\n349: 458-461.","journal-title":"Lancet"},{"key":"5115259_CR10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/oxfordjournals.aje.a009977","volume":"150","author":"PA Newcomb","year":"1999","unstructured":"Newcomb PA,Egan KM,Titus-Ernstoff L, et al. (1999) Lactation in relation to postmenopausal breast cancer. Am J Epidemiol\n150: 174-182.","journal-title":"Am J Epidemiol"},{"key":"5115259_CR11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/oxfordjournals.aje.a115313","volume":"130","author":"SA Beresford","year":"1989","unstructured":"Beresford SA,Coker AL (1989) Pictorially assisted recall of past hormone use in case-control studies. Am J Epidemiol\n130: 202-205.","journal-title":"Am J Epidemiol"},{"key":"5115259_CR12","first-page":"5","volume-title":"Statistical methods in cancer research. Volume I-The analysis of case-control studies","author":"NE Breslow","year":"1980","unstructured":"Breslow NE,Day NE (1980) Statistical methods in cancer research. Volume I-The analysis of case-control studies. IARC Scientific Publications (Lyon), 5-338."},{"key":"5115259_CR13","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jnci\/89.15.1088","volume":"89","author":"D Grady","year":"1997","unstructured":"Grady D,Ernster VL (1997) Hormone replacement therapy and endometrial cancer: are current regimens safe? J Natl Cancer Inst\n89: 1088-1089.","journal-title":"J Natl Cancer Inst"},{"key":"5115259_CR14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0002-9378(90)90838-X","volume":"162","author":"GL Rubin","year":"1990","unstructured":"Rubin GL,Peterson HB,Lee NC,Maes EF,Wingo PA,Becker S (1990) Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol\n162: 148-154.","journal-title":"Am J Obstet Gynecol"},{"key":"5115259_CR15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/BF00051699","volume":"7","author":"PK Green","year":"1996","unstructured":"Green PK,Weiss NS,McKnight B,Voigt LF,Beresford SA (1996) Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control\n7: 575-580.","journal-title":"Cancer Causes Control"},{"issue":"Suppl1","key":"5115259_CR16","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/0378-5122(96)01005-5","volume":"23","author":"E Hirvonen","year":"1996","unstructured":"Hirvonen E (1996) Progestins. Maturitas\n23(Suppl 1): S13-S18.","journal-title":"Maturitas"},{"key":"5115259_CR17","first-page":"69","volume-title":"Treatment of Postmenopausal Women: Basic and Clinical Aspects","author":"FZ Stanczyk","year":"1994","unstructured":"Stanczyk FZ (1994) Stucture-function relationships, potency, and pharmacokinetcis of progestogens. In: Lobo R. ed. Treatment of Postmenopausal Women: Basic and Clinical Aspects, New York: Raven Press, pp. 69-80."},{"key":"5115259_CR18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"Writing Group for the Women's Health Initiative Investigators","year":"2002","unstructured":"Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA\n288: 321-333.","journal-title":"JAMA"},{"key":"5115259_CR19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0015-0282(16)49215-0","volume":"45","author":"G Lane","year":"1986","unstructured":"Lane G,Siddle NC,Ryder TA,Pryse-Davies J,King RJ,Whitehead MI (1986) Is Provera the ideal progestogen for addition to postmenopausal estrogen therapy? Fertil Steril\n45: 345-352.","journal-title":"Fertil Steril"},{"key":"5115259_CR20","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1136\/bmj.280.6217.822","volume":"280","author":"ME Paterson","year":"1980","unstructured":"Paterson ME,Wade-Evans T,Sturdee DW,Thom MH,Studd JW (1980) Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Brit Med J\n280: 822-824.","journal-title":"Brit Med J"},{"key":"5115259_CR21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bjc.1988.44","volume":"57","author":"TJ Key","year":"1988","unstructured":"Key TJ,Pike MC (1988) The dose-effect relationship between \u2018unopposed\u2019 oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Brit J Cancer\n57: 205-212.","journal-title":"Brit J Cancer"},{"key":"5115259_CR22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/oxfordjournals.aje.a009352","volume":"146","author":"GA Greendale","year":"1997","unstructured":"Greendale GA,James MK,Espeland MA,Barrett-Connor E (1997) Can we measure prior postmenopausal estrogen\/progestin use? The Postmenopausal Estrogen\/Progestin Interventions Trial. The PEPI Investigators. Am J Epidemiol\n146: 763-770.","journal-title":"Am J Epidemiol"},{"key":"5115259_CR23","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/00001648-199905000-00012","volume":"10","author":"MG Jain","year":"1999","unstructured":"Jain MG,Rohan TE,Howe GR (1999) Agreement of self-reported use of menopausal hormone replacement therapy with physician reports. Epidemiol\n10: 260-263.","journal-title":"Epidemiol"},{"key":"5115259_CR24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/oxfordjournals.aje.a115572","volume":"131","author":"MT Goodman","year":"1990","unstructured":"Goodman MT,Nomura AM,Wilkens LR,Kolonel LN (1990) Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol\n131: 815-825.","journal-title":"Am J Epidemiol"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1023066304473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1023066304473\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1023066304473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T18:12:16Z","timestamp":1750961536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1023066304473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["5115259"],"URL":"https:\/\/doi.org\/10.1023\/a:1023066304473","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"type":"print","value":"0957-5243"},{"type":"electronic","value":"1573-7225"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}